-$0.40 Earnings Per Share Expected for GALAPAGOS NV/S (NASDAQ:GLPG) This Quarter

Equities analysts expect GALAPAGOS NV/S (NASDAQ:GLPG) to report earnings per share of ($0.40) for the current fiscal quarter, Zacks Investment Research reports. Three analysts have provided estimates for GALAPAGOS NV/S’s earnings, with estimates ranging from ($1.29) to $0.28. GALAPAGOS NV/S posted earnings per share of $0.34 during the same quarter last year, which would indicate a negative year-over-year growth rate of 217.6%. The company is scheduled to report its next quarterly earnings results after the market closes on Thursday, February 20th.

On average, analysts expect that GALAPAGOS NV/S will report full-year earnings of $5.75 per share for the current fiscal year, with EPS estimates ranging from $5.33 to $6.17. For the next fiscal year, analysts anticipate that the firm will post earnings of ($2.80) per share, with EPS estimates ranging from ($7.60) to $0.57. Zacks’ earnings per share averages are a mean average based on a survey of sell-side research analysts that follow GALAPAGOS NV/S.

GLPG has been the subject of a number of research analyst reports. Cantor Fitzgerald cut shares of GALAPAGOS NV/S from an “overweight” rating to a “neutral” rating and increased their target price for the company from $187.00 to $192.00 in a report on Tuesday, February 25th. They noted that the move was a valuation call. JPMorgan Chase & Co. dropped their target price on shares of GALAPAGOS NV/S from $205.00 to $200.00 and set a “neutral” rating for the company in a report on Monday, March 2nd. Zacks Investment Research raised shares of GALAPAGOS NV/S from a “hold” rating to a “buy” rating and set a $216.00 target price for the company in a report on Tuesday, March 10th. Nomura reaffirmed a “buy” rating and issued a $290.00 target price (up from $209.00) on shares of GALAPAGOS NV/S in a report on Wednesday, February 26th. Finally, Citigroup cut shares of GALAPAGOS NV/S from a “neutral” rating to an “underperform” rating and set a $213.00 target price for the company. in a report on Monday, February 24th. They noted that the move was a valuation call. Two analysts have rated the stock with a sell rating, nine have issued a hold rating, five have issued a buy rating and one has given a strong buy rating to the stock. GALAPAGOS NV/S currently has a consensus rating of “Hold” and an average price target of $224.55.

Several hedge funds have recently added to or reduced their stakes in the company. Macquarie Group Ltd. grew its position in shares of GALAPAGOS NV/S by 12.8% in the fourth quarter. Macquarie Group Ltd. now owns 8,004 shares of the biotechnology company’s stock valued at $1,655,000 after purchasing an additional 910 shares during the last quarter. RMR Wealth Builders acquired a new stake in shares of GALAPAGOS NV/S during the fourth quarter valued at approximately $82,000. Norges Bank acquired a new stake in shares of GALAPAGOS NV/S during the fourth quarter valued at approximately $14,478,000. 1832 Asset Management L.P. acquired a new stake in shares of GALAPAGOS NV/S during the fourth quarter valued at approximately $13,636,000. Finally, Geode Capital Management LLC raised its holdings in shares of GALAPAGOS NV/S by 108.4% during the fourth quarter. Geode Capital Management LLC now owns 11,965 shares of the biotechnology company’s stock valued at $2,474,000 after acquiring an additional 6,223 shares during the period. Institutional investors and hedge funds own 11.67% of the company’s stock.

GALAPAGOS NV/S stock traded down $5.35 during mid-day trading on Monday, reaching $182.14. The company had a trading volume of 356,064 shares, compared to its average volume of 324,697. GALAPAGOS NV/S has a 1 year low of $95.36 and a 1 year high of $274.03. The company has a debt-to-equity ratio of 0.01, a current ratio of 8.95 and a quick ratio of 8.95. The company has a market capitalization of $12.12 billion, a P/E ratio of 36.00 and a beta of 1.50. The stock’s 50-day simple moving average is $214.39 and its 200-day simple moving average is $196.20.

GALAPAGOS NV/S Company Profile

Galapagos NV, a clinical-stage biotechnology company, discovers, develops, and commercializes novel medicines. Its clinical stage programs include filgotinib, which is in Phase III clinical trials for the treatment of rheumatoid arthritis and Crohn's disease, Phase 2/3 trials for ulcerative colitis, and Phase II trials for multiple additional indications; GLPG1690, an autotaxin inhibitor, which is in Phase III clinical trial for the treatment of idiopathic pulmonary fibrosis; GLPG1972 that completed Phase 1b clinical trial for the treatment of osteoarthritis; and MOR106, which is in Phase II trials for atopic dermatitis patients.

Further Reading: Google Finance Portfolio Tips and Tricks

Get a free copy of the Zacks research report on GALAPAGOS NV/S (GLPG)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for GALAPAGOS NV/S (NASDAQ:GLPG)

Receive News & Ratings for GALAPAGOS NV/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GALAPAGOS NV/S and related companies with MarketBeat.com's FREE daily email newsletter.